Vilanterol (trifenatate) Catalog No.:M9740-2 Preclinical modeling of combined phosphatidylinositol-3-kinase

Preclinical modeling of combined phosphatidylinositol-3-kinase inhibition with endocrine therapy for estrogen receptor-positive breast cancer

leading to the dose-dependent cell growth inhibition and apoptosis induction in cells without wild-type p53

CAS Number: 68278-23-9

Metformin decreases hepatic glucose production and increases skeletal myocyte glucose uptake

IC50 Value: Target: SSRIsPipofezine is a tricyclic antidepressant (TCA) approved in Russia for the treatment of depression

Vilanterol (trifenatate) Catalog No.:M9740-2 Preclinical modeling of combined phosphatidylinositol-3-kinaseVilanterol, also known as GW 642444, is a long acting beta 2 agonist drug, which in May 2013 was approved in combination with fluticasone furoate for sale as Breo Ellipta by GlaxoSmithKline for the treatment of chronic obstructive pulmonary disease (COPD). Product information CAS Number: 503070 58 4 Molecular Weight: 774. 77 Formula: C44H49Cl2NO7 Chemical Name: 4 [(1R) 2 [(6 {2 [(2,6 dichlorophenyl)methoxy]ethoxy}hexyl)amino] 1 hydroxyethyl] 2